Summary by Futu AI
BeiGene announced the appointment of Shalini Sharp to its Board of Directors and Audit Committee, effective September 27, 2024. The Board size increased from 11 to 12 members. Sharp, 49, brings extensive experience in the pharmaceutical and financial sectors, currently serving on the boards of Neurocrine Biosciences and Organon & Co.Sharp will receive equity awards valued at $400,000 (pro-rated in the first year), annual cash compensation of $65,000 for board service and $17,500 for Audit Committee membership. She will serve as a Class III director until the 2025 annual meeting. BeiGene CEO John V. Oyler highlighted Sharp's global pharmaceutical leadership experience as valuable for the company's growth phase.Previously, Sharp held CFO positions at Ultragenyx Pharmaceuticals and Agenus Inc. She also served on boards of several biopharmaceutical companies. Sharp's appointment is expected to contribute to BeiGene's strategic growth and financial expertise as it expands globally and advances its cancer therapy pipeline.
